Efficacy of different salvage regimens in progressive unresectable pediatric low-grade glioma

被引:2
|
作者
El-Hemaly, Ahmed [1 ,2 ]
Taha, Hala [3 ,4 ]
Refaat, Amal [5 ,6 ]
Adel, Fatima [7 ]
Elbeltagy, Mohamed [8 ,9 ]
Arafah, Omar [2 ,10 ]
机构
[1] Childrens Canc Hosp Egypt 57357, Dept Pediat Oncol, Cairo 11617, Egypt
[2] Cairo Univ, NCI, Dept Pediat Oncol, Cairo 11796, Egypt
[3] Cairo Univ, NCI, Dept Pathol, Cairo 11796, Egypt
[4] Childrens Canc Hosp Egypt 57357, Dept Pathol, Cairo 11617, Egypt
[5] Cairo Univ, NCI, Dept Radiodiag, Cairo 11796, Egypt
[6] Childrens Canc Hosp Egypt 57357, Dept Radiodiag, Cairo 11617, Egypt
[7] Childrens Canc Hosp Egypt 57357, Dept Res, Cairo 11617, Egypt
[8] Cairo Univ, Kasr Al Ainy Sch Med, Dept Neurosurg, Cairo 11796, Egypt
[9] Childrens Canc Hosp Egypt 57357, Dept Neurosurg, Cairo 11617, Egypt
[10] Cairo Univ, NCI, Dept Pediat Oncol, 1 Fom El Khaleeg St,Kasr El Aini Ave, Cairo 11796, Egypt
关键词
pediatric; progressive; unresectable; low-grade glioma; salvage chemotherapy; neurofibromatosis; 1; PHASE-II; CARBOPLATIN; CHILDREN; CHEMOTHERAPY; VINCRISTINE; RECURRENT; TUMORS;
D O I
10.3892/ol.2022.13527
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Multiple salvage chemotherapy regimens are used in progressive low-grade glioma (LGG), with no single regimen being more effective than any other. In the present study, different salvage therapies were compared with regard to the response rate, overall survival (OS) rate, event-free survival (EFS) rate and visual outcome in 70 patients with pediatric LGG. Age was found to significantly affect the EFS and OS rates (P<0.001). The visual outcome was the same between the three regimens. The 2-year EFS and OS rates of the vincristine/carboplatin, monthly carboplatin and weekly vinblastine regimens were 64.7 and 70.6%, 71.0 and 85.0%, and 56.0 and 62.7%, respectively (P=0.6 for EFS; P=0.56 for OS). Overall, the present study demonstrated that age had a significant impact on survival. The three salvage regimens used were equally effective with regard to the radiological response and visual outcome. However, further randomized controlled trials are required to detect the optimal salvage therapy.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Targeted Therapy in Pediatric Low-Grade Glioma
    Kilday, John-Paul
    Bartels, Ute Katharina
    Bouffet, Eric
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2014, 14 (04)
  • [22] Targeted therapy for pediatric low-grade glioma
    Juan Pablo Muñoz Pérez
    Jordi Muchart
    Vicente Santa-María López
    Mariona Suñol Capella
    Noelia Salvador
    Sara Pérez Jaume
    Ofelia Cruz Martínez
    Andrés Morales La Madrid
    Child's Nervous System, 2021, 37 : 2511 - 2520
  • [23] Targeted Therapy in Pediatric Low-Grade Glioma
    John-Paul Kilday
    Ute Katharina Bartels
    Eric Bouffet
    Current Neurology and Neuroscience Reports, 2014, 14
  • [24] Molecular markers for pediatric low-grade glioma
    Levine, Adrian B.
    Hawkins, Cynthia E.
    CHILDS NERVOUS SYSTEM, 2024, 40 (10) : 3223 - 3228
  • [25] Medical sequelae of pediatric low-grade glioma
    Schouten-van Meeteren, AYNS
    Lee, WL
    Mandl, E
    Vandertop, WP
    NEURO-ONCOLOGY, 2004, 6 (04) : 443 - 443
  • [26] Intramedullary pediatric low-grade glioma of the spine
    Lu, Victor M.
    Jallo, George I.
    Shimony, Nir
    CHILDS NERVOUS SYSTEM, 2024, 40 (10) : 3107 - 3117
  • [27] Targeted therapy for pediatric low-grade glioma
    Perez, Juan Pablo Munoz
    Muchart, Jordi
    Lopez, Vicente Santa-Maria
    Capella, Mariona Sunol
    Salvador, Noelia
    Jaume, Sara Perez
    Martinez, Ofelia Cruz
    La Madrid, Andres Morales
    CHILDS NERVOUS SYSTEM, 2021, 37 (08) : 2511 - 2520
  • [28] Temozolomide in the treatment of progressive low-grade glioma.
    Silva, NS
    Paes, V
    Galeana, J
    Pascalicchio, AP
    Galväo, C
    Cavalheiro, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 806S - 806S
  • [29] Efficacy and safety of bevacizumab in progressive pediatric low-grade glioma: a systematic review and meta-analysis of outcome rates
    Lu, Victor M.
    Welby, John P.
    Nesvick, Cody L.
    Daniels, David J.
    NEURO-ONCOLOGY PRACTICE, 2020, 7 (04) : 359 - 368
  • [30] Trametinib for progressive pediatric low-grade gliomas
    Maria Kondyli
    Valérie Larouche
    Christine Saint-Martin
    Benjamin Ellezam
    Lauranne Pouliot
    Daniel Sinnett
    Geneviève Legault
    Louis Crevier
    Alex Weil
    Jean-Pierre Farmer
    Nada Jabado
    Sébastien Perreault
    Journal of Neuro-Oncology, 2018, 140 : 435 - 444